UVENILE IDIOPATHIC ARTHRITIS (JIA), previously called juvenile rheumatoid arthritis until recent reclassification, is the most common rheumatic disease of childhood. 1 JIA is defined as persistent arthritis for more than 6 weeks with an onset at less than 16 years of age, after excluding other causes. JIA consists of several subtypes (TABLE 1, FIGURE 1). 2,3 Recent data show that most children never achieve a long-term remission, thus the burden of disease to the patient, family, and ultimately society is large. 4-14 It is important to recognize the disease and to treat early, before soft-tissue deformities and joint damage become irreversible (FIGURE 2). The treatment of JIA combines antiinflammatory and immunomodulatory medications with physical and occupational therapy, an occasional need for surgery, nutritional support, and psychosocial and educational partnership with patients and parents. The treatment of JIA has changed markedly in the last 15 years, yet many children are not treated by pediatric rheumatologists. 15 This review summarizes the current evidence-based medical therapy for JIA (not including uveitis) and offers a rational approach for the treatment of the various subtypes of disease. METHODS Data Sources A literature search was performed for English-language clinical trials in JIA, with an emphasis on randomized trials. We used MEDLINE, EMBASE, and Cochrane and systematic reviews to identify trials from 1966 to 2005 and reviewed abstracts from the 2003 to 2004 major rheumatology and pediatric meetings. Besides JIA, we used other terms of chronic arthritidies of childhood and searched all drugs used to treat inflammatory arthritidies (list available on request). A total of 279 studies were identified including 34 randomized and 28 double-blinded trials. Fourteen controlled trials were for nonsteroidal anti-inflammatory drugs (NSAIDs), 14 for diseasemodifying antirheumatic drugs (DMARDs) or immunosuppressive medications or systemic corticosteroids, 3 for intra-articular corticosteroid injections, and 3 for biologic-See also Patient Page.